What Is Ropeginterferon alfa-2b?
Ropeginterferon alfa-2b is an FDA-approved medication for Polycythemia Vera, administered according to approved prescribing information. This medication is typically given as a subcutaneous injection, meaning it is injected under the skin. Clinical trials have investigated specific dosing schedules, such as an initial dose of 250 µg at Day 1, increasing to 350 µg at Week 2, and a target optimal dose of 500 µg at Week 4, administered every two weeks.
Beyond its approved indication, ropeginterferon alfa-2b is currently being studied in clinical trials for a variety of other conditions. These include:
- Myelofibrosis
- Myeloproliferative Neoplasm
- Chronic Myeloid Leukemia
- Essential Thrombocythemia
- Primary Myelofibrosis
- JAK2 Mutation
- Hepatitis D
- Hepatocellular Carcinoma
- COVID-19
The drug aims to manage disease progression and symptoms in these various conditions, with a total of 27 trials having been conducted or are ongoing, involving 2,268 participants.
Uses and Conditions Under Study
Ropeginterferon alfa-2b is primarily studied for various blood disorders, particularly myeloproliferative neoplasms (MPNs). Polycythemia Vera (PV) is one such condition, characterized by the overproduction of red blood cells, which can lead to blood clots and other serious complications. Ropeginterferon alfa-2b is an approved treatment for PV and has been investigated in 4 trials for this condition, aiming to reduce the need for phlebotomy and manage disease progression. Other related conditions under investigation include:
- Myelofibrosis (2 trials)
- Myeloproliferative Neoplasm (2 trials)
- Essential Thrombocythemia (2 trials)
- Primary Myelofibrosis (2 trials)
These conditions involve the abnormal growth of blood cells in the bone marrow, and the drug is being explored for its potential to control cell proliferation and improve patient outcomes. Additionally, the drug is being studied for its role in conditions involving JAK2 Mutation (1 trial), a common genetic mutation found in many MPNs.
Beyond MPNs, ropeginterferon alfa-2b is also being investigated for other types of cancer. This includes Chronic Myeloid Leukemia (CML), a cancer of the white blood cells, which is being studied in 2 trials. Hepatocellular Carcinoma, a type of liver cancer, is also the subject of 1 trial. In these cancers, ropeginterferon alfa-2b's mechanism may involve modulating immune responses or directly affecting cancer cell growth.
Furthermore, ropeginterferon alfa-2b has been explored for infectious diseases. It is being studied in 2 trials for COVID-19, suggesting a potential role in managing viral infections or their associated inflammatory responses. Hepatitis D, a severe liver infection, is also being investigated in 1 trial, where the drug might help in controlling viral replication and liver inflammation.
Dosing
Ropeginterferon alfa-2b, also known by the tradename BESREMi®, is primarily administered as a subcutaneous (SC) injection. This means the medication is injected under the skin. The most commonly studied dosing regimen involves administration every two weeks, sometimes with a flexibility of plus or minus 3 days.
In clinical trials, specific strengths and titration schedules have been investigated. For example, a typical regimen might begin with an initial dose of 250 µg on Day 1. This could then be increased to 350 µg at Week 2, with a target optimal dose of 500 µg reached at Week 4. This particular dosing schedule has been studied for conditions such as Polycythemia Vera, where it aims to manage blood cell counts.
While specific doses for all conditions under study are not detailed, the general approach involves subcutaneous injections on a bi-weekly schedule. The data provided does not specify different dosing guidelines for pediatric patients; all described regimens appear to be for adult populations. Phlebotomy, a procedure to remove blood, may be conducted if confirmed hematocrit (Hct) levels reach or exceed 48%, or if confirmed Hct is 3% higher than baseline.
Side Effects
Detailed information on the frequency of specific side effects for Ropeginterferon alfa-2b, including comparisons to placebo, is not available from the provided clinical trial data. In a study evaluating Ropeginterferon alfa-2b in patients with myelofibrosis (NCT02370329), 10 out of 11 participants (approximately 91%) experienced a Grade 3 or higher adverse event. Grade 3+ adverse events are considered severe or medically significant according to the National Cancer Institute Common Terminology Criteria for Adverse Events.
Clinical Trial Results
Myelofibrosis
In a clinical trial (NCT02370329) investigating Ropeginterferon alfa-2b (also known as P1101) in patients with myelofibrosis, all 11 participants achieved a best overall response. This response was determined by International Working Group Criteria and included complete remission, partial remission, or clinical improvement. Specific breakdowns for each type of response were not provided in the data.
Data on the median progression-free survival time for patients treated with Ropeginterferon alfa-2b in this study was not available.
Currently Recruiting Trials
Ropeginterferon alfa-2b is currently being investigated in several clinical trials for various conditions. These studies aim to gather more information about its safety and effectiveness, and they are actively seeking volunteers to participate. Here are some of the trials currently recruiting:
- A Phase I/IB study, NCT07047885, is underway to identify the recommended Phase II dose of Ropeginterferon alfa-2b in patients with Cutaneous T-Cell Lymphoma (CTCL). This single-center study, sponsored by H. Lee Moffitt Cancer Center, plans to enroll 38 participants who have not responded sufficiently to previous therapies.
- For adult patients with Primary Myelofibrosis (PMF) at an early stage or low to medium risk, PharmaEssentia is sponsoring a Phase 3 double-blind clinical trial, NCT06468033. This study aims to test Ropeginterferon alfa-2b (P1101) and is recruiting 150 participants.
- The University of Hong Kong is conducting a Phase 2 open-label study, NCT06770842, for patients with Myelofibrosis (including Primary Myelofibrosis, Post Polycythemia Myelofibrosis, and Post Essential Thrombocythaemia Myelofibrosis) who have shown a suboptimal response to ruxolitinib alone. Approximately 20 patients will be enrolled to receive Ropeginterferon alfa 2b in addition to their stable ruxolitinib dose.
- A multi-center Phase 2 study, NCT05731245, sponsored by National Taiwan University Hospital, is assessing the efficacy and safety of Ropeginterferon alfa-2b in 50 patients with pre-fibrotic primary myelofibrosis or DIPSS low/intermediate-1 risk myelofibrosis over 24 months.
- PharmaEssentia Japan K.K. is sponsoring a Phase 3 open-label extension study, NCT04655092, for patients with Polycythemia Vera (PV) or Essential Thrombocythemia (ET) who have completed earlier Phase 2 or Phase 3 studies. This trial is designed to evaluate the long-term efficacy, safety, and tolerability of P1101 (Ropeginterferon alfa-2b) and is enrolling 67 participants.
Where to Participate
Participation in clinical trials for Ropeginterferon alfa-2b is currently focused in a specific region. The recruiting trial for Cutaneous T-Cell Lymphoma (NCT07047885) is based at a single site in the United States.
The primary location for this study is:
- Tampa, Florida
Eligibility for this particular study specifies that participants must be between 18 and 20 years of age. All genders are welcome, but the study is not open to healthy volunteers or children.
Development Timeline
The journey of Ropeginterferon alfa-2b in clinical development began on February 24, 2015, marking the start of its extensive research. Since then, a total of 27 clinical trials have been initiated, involving 2,268 participants, with the latest trial projected to conclude in April 2026.
Early investigations into Ropeginterferon alfa-2b initially explored its potential for conditions such as IBS-C and hyperphosphatemia. However, the development pipeline quickly expanded, demonstrating the drug's versatility across a broader range of diseases.
Key areas of focus emerged, particularly within Myeloproliferative Neoplasms, including Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia. The drug also entered studies for Chronic Myeloid Leukemia, Hepatitis D, and Hepatocellular Carcinoma. Notably, its potential was even explored in the context of COVID-19, highlighting the breadth of its therapeutic investigation.
Research has progressed through various stages, with a significant number of studies reaching Phase 2 (10 trials) and Phase 3 (6 trials), indicating advanced stages of clinical evaluation. Leading the charge in this development are sponsors such as National Taiwan University Hospital and PharmaEssentia, alongside several other academic and pharmaceutical institutions, driving forward the understanding and potential applications of Ropeginterferon alfa-2b.